<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295814</url>
  </required_header>
  <id_info>
    <org_study_id>IMM 10-0061</org_study_id>
    <nct_id>NCT01295814</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Adalimumab to Treat Interstitial Cystitis</brief_title>
  <official_title>An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICStudy, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ICStudy, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate an investigational treatment for interstitial
      cystitis. Interstitial cystitis is a chronic bladder disease that includes the following
      symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and
      bladder discomfort relieved by voiding.

      Presently, there is no cure for interstitial cystitis. The response to current treatments is
      poor. Patients with interstitial cystitis have a poorer quality of life. The cause of
      interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for
      improving the symptoms of patients with interstitial cystitis. Humira® is an injectable
      anti-inflammatory medication that has been available for use since December 31, 2002. Humira®
      has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing
      spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial
      cystitis. This study will evaluate an investigational use of Humira® for the treatment of
      interstitial cystitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial cystitis (IC) is a chronic disabling bladder syndrome characterized by urinary
      frequency, nocturia, urinary urgency, and pain with bladder filling—relieved by emptying.
      There is no cure for IC and the treatment options are suboptimal. Patients with IC report
      significant negative effects on their physical and mental quality of life. The etiology of IC
      is unknown. Certain aspects of IC suggest that autoimmunity may play a role in initiating or
      sustaining the chronic inflammatory response. Bladder biopsies of patients with IC
      demonstrate an increase number of mast cells. Mast cell activation with the release of tumor
      necrosis factor (TNF) may mediate this bladder inflammation. Humira® (adalimumab) is a
      medication that blocks the effect of TNF. Humira® (adalimumab) is FDA approved for the
      treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease.
      These diseases are similar to IC. In this study, the hypothesis being tested is that Humira®
      (adalimumab) will show efficacy at reducing the symptoms of IC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score</measure>
    <time_frame>Baseline/12 Weeks</time_frame>
    <description>Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial Cystitis Symptom Index (ICSI)</measure>
    <time_frame>Baseline/ 12 weeks</time_frame>
    <description>Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Cystitis Problem Index (ICPI)</measure>
    <time_frame>Baseline/12 Weeks</time_frame>
    <description>Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Pain Urgency/Frequency (PUF) Score</measure>
    <time_frame>Baseline12 Weeks</time_frame>
    <description>Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Response Assessment (GRA)</measure>
    <time_frame>Measured at12 Weeks</time_frame>
    <description>Percent(%) of patients who reported 50% or greater overall improvement in their condition.
Score on a scale range (improvement 0%-100%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
    <arm_group_label>adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>inactive drug</intervention_name>
    <description>80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
    <arm_group_label>Inactive drug</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial
             Cystitis

          -  Currently have symptoms of urinary urgency, frequency or pain for more than 6 months

          -  Urinating at least 7 times a day or having some urgency or pain (measured on linear
             analog scales)

          -  Must be post-menopausal or surgically sterile or willing to use an adequate form of
             birth control

          -  Not pregnant or lactating

          -  Capable of voiding independently

          -  Willing to provide informed consent to participate

        Exclusion Criteria:

          -  Have symptoms that are presently relieved on other medications for interstitial
             cystitis

          -  Have absence of nocturia

          -  Have symptoms that are relieved by antimicrobials or antibiotics.

          -  Have a body mass index (BMI) of &gt;39 kg/m2

          -  Have uncontrolled hypertension

          -  Have Type I or type 2 diabetes

          -  Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection,
             or who are known carriers (Hepatitis B) at Screening

          -  Have a positive tuberculosis test at screening

          -  Have had a urinary tract infection for 6 weeks

          -  Have had bacterial cystitis in previous 3 months

          -  Have had previous exposure to Humira® (adalimumab)

          -  Have taken investigational medication within 30 days of screening

          -  Have any other condition/disease which, in the opinion of the investigator, could
             compromise subject safety or confound the interpretation of study results

          -  Are unable or unwilling to comply with protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip C Bosch, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Philip C. Bosch, MD</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014 Jan;191(1):77-82. doi: 10.1016/j.juro.2013.06.038. Epub 2013 Jun 20.</citation>
    <PMID>23792149</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>July 20, 2013</results_first_submitted>
  <results_first_submitted_qc>July 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <last_update_submitted>July 12, 2015</last_update_submitted>
  <last_update_submitted_qc>July 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ICStudy, LLC</investigator_affiliation>
    <investigator_full_name>Philip C. Bosch, M.D.</investigator_full_name>
    <investigator_title>Urologist</investigator_title>
  </responsible_party>
  <keyword>Interstitial cystitis</keyword>
  <keyword>Humira</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subject were recruited from medical practices and by advertisement starting March 2011 through January 2013.</recruitment_details>
      <pre_assignment_details>A total of 4 subjects did not meet screening criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inactive Drug</title>
          <description>inactive drug : placebo</description>
        </group>
        <group group_id="P2">
          <title>Adalimumab</title>
          <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inactive Drug</title>
          <description>inactive drug : placebo</description>
        </group>
        <group group_id="B2">
          <title>Adalimumab</title>
          <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="13.4"/>
                    <measurement group_id="B2" value="45.2" spread="14"/>
                    <measurement group_id="B3" value="45.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score</title>
        <description>Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)</description>
        <time_frame>Baseline/12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Drug</title>
            <description>inactive drug : placebo</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
          </group>
        </group_list>
        <measure>
          <title>O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score</title>
          <description>Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="4.9"/>
                    <measurement group_id="O2" value="27.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="10.7"/>
                    <measurement group_id="O2" value="19.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study had acceptable sensitivity with a statistical power of 0.99 (99%) for the improvement in the adalimumab group from baseline to week 12.
The study had acceptable sensitivity with a statistical power of 0.92 (92%) for the improvement in the placebo group from baseline to week 12.</non_inferiority_desc>
            <p_value>0.75</p_value>
            <p_value_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
            <estimate_desc>Confidence interval was improvement in OSPI in the adalimumab group from baseline to week 12.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interstitial Cystitis Symptom Index (ICSI)</title>
        <description>Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)</description>
        <time_frame>Baseline/ 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Drug</title>
            <description>inactive drug : placebo</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
          </group>
        </group_list>
        <measure>
          <title>Interstitial Cystitis Symptom Index (ICSI)</title>
          <description>Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="3.1"/>
                    <measurement group_id="O2" value="14.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="5.7"/>
                    <measurement group_id="O2" value="10.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <p_value_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
            <estimate_desc>Confidence interval was improvement in ICSI in the adalimumab group from baseline to week 12.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interstitial Cystitis Problem Index (ICPI)</title>
        <description>Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)</description>
        <time_frame>Baseline/12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Drug</title>
            <description>inactive drug : placebo</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
          </group>
        </group_list>
        <measure>
          <title>Interstitial Cystitis Problem Index (ICPI)</title>
          <description>Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="2.2"/>
                    <measurement group_id="O2" value="13.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="5.1"/>
                    <measurement group_id="O2" value="9.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>Confidence interval was improvement in ICPI in the adalimumab group from baseline to week 12.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pelvic Pain Urgency/Frequency (PUF) Score</title>
        <description>Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)</description>
        <time_frame>Baseline12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Drug</title>
            <description>inactive drug : placebo</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvic Pain Urgency/Frequency (PUF) Score</title>
          <description>Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="3.9"/>
                    <measurement group_id="O2" value="24.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="8.7"/>
                    <measurement group_id="O2" value="18.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
            <estimate_desc>Confidence interval was improvement in PUF in the adalimumab group from baseline to week 12.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Response Assessment (GRA)</title>
        <description>Percent(%) of patients who reported 50% or greater overall improvement in their condition.
Score on a scale range (improvement 0%-100%)</description>
        <time_frame>Measured at12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Drug</title>
            <description>inactive drug : placebo</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
          </group>
        </group_list>
        <measure>
          <title>Global Response Assessment (GRA)</title>
          <description>Percent(%) of patients who reported 50% or greater overall improvement in their condition.
Score on a scale range (improvement 0%-100%)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>Statistical improvement in the adalimumab group compared to the placebo group from baseline to week 12.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>March 2011 to March 2013</desc>
      <group_list>
        <group group_id="E1">
          <title>Inactive Drug</title>
          <description>inactive drug : placebo</description>
        </group>
        <group group_id="E2">
          <title>Adalimumab</title>
          <description>Adalimumab : 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Does not include headache</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip C. Bosch, MD</name_or_title>
      <organization>IC Study, LLC</organization>
      <phone>760-743-3135</phone>
      <email>pboschmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

